Natco Pharma

Natco Pharma EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Natco Pharma (NATCOPHARM.NS) as of Oct 23, 2026 is 10.45. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 10.49 — a change of -0.36% (lower).

EV/FCF

10.45

YoY

-0.36%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Natco Pharma is 2026 10.45 . EV/FCF (Enterprise Value to Free Cash Flow) of Natco Pharma was 2025 10.49 . It decreases by -0.36% lower compared to the previous year.

The Natco Pharma EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2019
73.09 INR
Jan 1, 2020
259.53 INR
Jan 1, 2021
345.56 INR
Jan 1, 2022
-78.90 INR
Jan 1, 2023
23.09 INR
Jan 1, 2024
16.13 INR
Jan 1, 2025
10.49 INR
Jan 1, 2026
10.45 INR
The Natco Pharma EV/FCF history
YEAREV/FCFYoY
10.45-0.36%
10.49-34.98%
16.13-30.14%
23.09-129.27%
-78.90-122.83%
345.56+33.15%
259.53+255.10%
73.09-81.02%
385.10+60.66%
239.69-183.14%
-288.32-52.49%
-606.84-227.39%
476.36—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Natco Pharma Stock analysis

What does Natco Pharma do? Natco Pharma Ltd is an Indian pharmaceutical company that was founded in 1981. It is headquartered in Hyderabad, India and also operates branches in other parts of India and overseas. History Natco Pharma Ltd was founded by Dr. Devinder Pal Singh. The company started as a small generic drug manufacturing company but gradually expanded and today is one of the leading pharmaceutical companies in India. In the early 2000s, Natco Pharma Ltd entered the international market and has since conducted many important partnerships and acquisitions to expand its business. Business model Natco Pharma Ltd's business model focuses on the research, development, and manufacturing of drugs used in various therapeutic areas. The company primarily produces generics but also biosimilars and innovative products. Natco Pharma Ltd aims to provide affordable and accessible medications to patients in India and worldwide. Products and divisions Natco Pharma Ltd produces a wide range of medications divided into various divisions. The company's main divisions include oncology, hepatitis C, nephrology, neurology, cardiology, and anti-infectives. Natco Pharma Ltd also offers a range of biosimilars, including pegfilgrastim and trastuzumab, and has launched innovative products such as Natdac (daclatasvir) and Hepcinat LP (sofosbuvir and ledipasvir). The company also has a separate department for the production of active pharmaceutical ingredients (APIs) and has multiple manufacturing facilities in different parts of India certified by strict international quality standards (such as USFDA, UK-MHRA, and TGA). Activities Natco Pharma Ltd has been involved in several patent litigation cases to facilitate access to affordable generic medications. A significant example is the patented cancer drug Nexavar by Bayer. Natco Pharma Ltd won a long legal battle, allowing it to bring a cheaper version of the drug to the market. Natco Pharma Ltd has also built partnerships with other pharmaceutical companies to promote the distribution of its medications on a global level. One important collaboration of the company is with Mylan to manufacture affordable versions of HIV/AIDS medications for developing countries. Conclusion Natco Pharma Ltd is a strong example of a company that has been able to grow through quality, research, and affordable products. It has also been involved in several patent disputes to improve access to affordable medications. The wide range of medications and divisions shows that Natco Pharma Ltd is a significant player in the Indian and international market. Natco Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Natco Pharma stock

EV/FCF (Enterprise Value to Free Cash Flow) of Natco Pharma is 10.45 in 2026.

EV/FCF (Enterprise Value to Free Cash Flow) of Natco Pharma changed from 10.49 to 10.45, representing a -0.36% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Natco Pharma since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Natco Pharma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Natco Pharma

All Key Metrics — Natco Pharma